ERBB2 and breast carcinoma: Modern breast cancer treatments are based on these two validated biomarkers since ErbB2-positive breast cancers are treated with the ErbB2-targeted antibody, trastuzumab (Herceptin©), while ER-positive breast cancers are treated with either antiestrogens or estrogen-ablating aromatase inhibitors.